Of all the peptides discussed in research communities, GHK-Cu has one of the longest and most credible research trails. First isolated from human plasma in 1973 by biochemist Loren Pickart, the copper tripeptide has since accumulated decades of peer-reviewed research — making it a genuinely unusual case in a field often characterized by thin preclinical evidence and ambitious anecdote.
This isn't to say GHK-Cu is a solved science. It isn't. But the body of evidence is substantially richer than for most peptides in this niche, and understanding what it actually shows — versus what gets claimed on supplement sites — is worth the effort.
Context note. GHK-Cu is available both as an injectable research peptide and as a cosmetic ingredient in topical skincare products. The evidence base differs significantly between routes. Topical data is generally stronger and better controlled. Injectable systemic use extrapolates from in vitro and animal data more heavily.
GHK-Cu is a naturally occurring tripeptide (glycine-histidine-lysine) that binds copper ions (Cu2+). It was first isolated from human plasma in 1973 by Loren Pickart. GHK-Cu appears to act as a biological signal for tissue remodeling — it upregulates collagen and glycosaminoglycan synthesis, stimulates angiogenesis, and has been shown to modulate gene expression across hundreds of genes involved in repair, inflammation, and antioxidant response.
What GHK-Cu Actually Is
GHK-Cu is a tripeptide: glycine-histidine-lysine (GHK) bound to a copper ion (Cu²⁺). It occurs naturally in human plasma, saliva, and urine, and its plasma concentration declines significantly with age — from approximately 200 ng/mL at age 20 to around 80 ng/mL by age 60. This decline pattern has led researchers to hypothesize a role in the age-related loss of regenerative capacity, though causality remains unproven.
The tripeptide's biological activity appears to be broad and somewhat unusual. Unlike most peptides that bind to a specific receptor and trigger a discrete pathway, GHK-Cu seems to act as a general tissue remodeling signal — upregulating repair processes, modulating inflammatory response, and influencing gene expression across a surprisingly large number of pathways.
The Research Evidence: What's Actually Established
🔬 Wound Healing
The strongest body of evidence. Multiple controlled studies show accelerated wound closure, increased collagen deposition, and improved wound tensile strength in animal models. Some human wound care studies show similar effects.
🔬 Collagen Synthesis
GHK-Cu stimulates collagen I, III, and IV production in fibroblast cultures. It also increases glycosaminoglycans and decorin — key components of the extracellular matrix. In vitro evidence is consistent across labs.
🔬 Skin Regeneration (Topical)
Several clinical trials in cosmetic dermatology show measurable improvements in skin density, elasticity, and fine line reduction with topical GHK-Cu at concentrations of 0.1–2%. Considered among the best-supported peptide ingredients in cosmeceuticals.
🔬 Gene Expression
Loren Pickart's research identified modulation of 4,000+ human genes by GHK-Cu — including upregulation of repair and antioxidant genes and downregulation of inflammatory and pro-oncogenic genes. Striking findings that need more in vivo validation.
🔬 Anti-inflammatory
GHK-Cu has shown consistent anti-inflammatory effects in multiple tissue types, including inhibition of TNF-alpha and IL-6 in cell culture studies. Effects in live organisms are less characterized.
🔬 Hair Growth
Some studies suggest GHK-Cu promotes hair follicle size and growth, possibly via increased blood vessel formation around follicles. Data is limited and mostly in vitro or rodent models.
GHK-Cu vs. Other Repair Peptides
It's worth clarifying where GHK-Cu fits relative to the more commonly discussed peptides in the research community. BPC-157 and TB-500 dominate conversations about injury repair and musculoskeletal recovery. GHK-Cu occupies a different but complementary niche:
| Peptide | Primary Research Focus | Route | Evidence Quality |
|---|---|---|---|
| GHK-Cu | Skin, wound healing, collagen, gene expression | Topical / SubQ | Moderate–Good (decades of research) |
| BPC-157 | Tendon, gut, neuro, angiogenesis | SubQ / IM / oral | Moderate (mostly animal) |
| TB-500 | Actin dynamics, systemic repair, cardiac | SubQ / IM | Moderate (animal + some human trials) |
Some researchers stack GHK-Cu with BPC-157, arguing the two cover complementary repair mechanisms — BPC-157 for angiogenesis and growth factor stimulation, GHK-Cu for collagen remodeling and extracellular matrix support. There's no controlled data on this combination specifically, but mechanistically the logic isn't unreasonable.
Dosing: What Research Protocols Use
For injectable systemic use, most community protocols use 1–3 mg per day via subcutaneous injection, run in 4–8 week cycles. Some protocols use lower doses of 0.5–1 mg for maintenance. The injectable evidence base is substantially thinner than topical, so these numbers extrapolate from the topical and animal literature more heavily than researchers would ideally prefer.
Topical concentrations in validated cosmetic research range from 0.1% to 2%. Most high-quality topical products with GHK-Cu sit in the 0.2–1% range. Higher concentrations don't necessarily produce better results and may theoretically over-saturate copper uptake in tissue.
Practical note: If your primary interest is skin quality and tissue remodeling support rather than acute injury repair, a topical GHK-Cu product may offer the best evidence-to-risk ratio. The topical evidence is better controlled than the injectable human data. Injectable protocols are more common among those stacking GHK-Cu with other systemic peptides.
The Gene Expression Angle — and Why It Needs Caution
The claim that GHK-Cu "modulates 31% of the human genome" is technically derived from Loren Pickart's bioinformatic analysis of gene expression databases — not from a clinical trial. The finding that a peptide affects expression of 4,000+ genes doesn't mean it does so in a clinically meaningful way in a living human at any given dose. Gene expression data in cell cultures often doesn't translate linearly to organismal outcomes.
This doesn't invalidate the gene expression research — it's genuinely interesting and may explain GHK-Cu's broad biological effects. But it should be held at arm's length relative to the more directly validated wound healing and collagen data, which rests on cleaner experimental evidence.
Research-Grade Sourcing
WolveStack partners with Ascension Peptides for independently third-party tested research compounds with published COAs.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Complete Guide
GHK : Benefits, Dosage, Side Effects & Research
Frequently Asked Questions
GHK-Cu is a naturally occurring tripeptide (glycine-histidine-lysine) that binds copper ions. First isolated from human plasma in 1973, it appears to act as a biological signal for tissue remodeling — upregulating collagen and glycosaminoglycan synthesis, stimulating angiogenesis, and modulating gene expression across hundreds of repair, inflammation, and antioxidant pathways.
GHK-Cu has shown consistent results in wound healing research: faster wound closure, increased collagen density, improved skin elasticity, and reduced scar formation. In controlled cosmetic studies, topical GHK-Cu demonstrated reductions in fine lines, improved skin firmness, and recovery of skin density. It's been incorporated into premium cosmetic formulations for decades based on this evidence.
No. GHK-Cu is a copper-binding peptide primarily studied for wound healing and skin regeneration. BPC-157 is a synthetic fragment from gastric juice with research focused on tendon, gut, and musculoskeletal repair. TB-500 is a Thymosin Beta-4 analog focused on actin dynamics. They operate through completely different mechanisms.
Injectable research protocols typically use 1–3 mg per day via subcutaneous injection, run in 4–8 week cycles. There's limited human data on long-term systemic injectable use, so most research references shorter cycle durations with breaks. Use the peptide calculator to work out reconstitution math.
Yes, and this is where the strongest controlled evidence exists. GHK-Cu penetrates skin effectively and has been validated in multiple cosmetic and wound healing studies. Many researchers start with topical use before considering injectable protocols. Topical GHK-Cu serums and creams are commercially available through cosmetic vendors.
Loren Pickart's research found GHK-Cu modulates expression of over 4,000 human genes — including upregulation of repair, antioxidant, and anti-inflammatory genes, and downregulation of genes associated with cancer progression and inflammation. These in vitro findings are striking but require more in vivo validation to determine clinical relevance at typical research doses.
Interested in stacking GHK-Cu with BPC-157 or TB-500? Read the Wolverine Stack guide for a foundation on combining repair peptides, then use the dosing calculator for your reconstitution math.